Sleep disturbances in Parkinson's disease: The contribution of dopamine in REM sleep regulation

Sleep Medicine Reviews

Volumn 17, Issue 5, 2013, Pages 367-375

  Lima, Marcelo M S ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Dopamine; Parkinson's disease; Pedunculopontine tegmental nucleus; Rapid eye movement (REM) behavior disorder; Rapid eye movement (REM) sleep; Reticular formation; Sleep; Substantia nigra pars compacta; Ventral tegmental area

Indexed keywords

APOMORPHINE; CABERGOLINE; CLOZAPINE; DOPAMINE; LEVODOPA;

AKATHISIA; DAYTIME SOMNOLENCE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; HUMAN; INSOMNIA; NERVE CELL; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; PARASOMNIA; PARKINSON DISEASE; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; PERIODIC LIMB MOVEMENT DISORDER; REM SLEEP; RESTLESS LEGS SYNDROME; RETICULAR FORMATION; REVIEW; SLEEP; SLEEP DISORDER; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM;

DOPAMINE; PARKINSON'S DISEASE; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; RAPID EYE MOVEMENT (REM) BEHAVIOR DISORDER; RAPID EYE MOVEMENT (REM) SLEEP; RETICULAR FORMATION; SLEEP; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTAL AREA;

DOPAMINE; HUMANS; PARKINSON DISEASE; SLEEP DISORDERS; SLEEP, REM;

EID: 84881243057     PISSN: 10870792     EISSN: 15322955     Source Type: Journal    
DOI: 10.1016/j.smrv.2012.10.006     Document Type: Review

References (86)

1. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. NEngl J Med 1998, 339:1044-1053.
2. Lang A.E., Lozano A.M. Parkinson's disease. Second of two parts. NEngl J Med 1998, 339:1130-1143.
3. Parkinson J. An essay on the shaking palsy 1817, Sherwood, London. S. NaJ (Ed.).
4. De Cock V.C., Vidailhet M., Arnulf I. Sleep disturbances in patients with parkinsonism. Nat Clin Pract Neurol 2008, 4:254-266.
5. Abbott R.D., Ross G.W., White L.R., Tanner C.M., Masaki K.H., Nelson J.S., et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005, 65:1442-1446.
6. Postuma R.B., Montplaisir J. Potential early markers of Parkinson's disease in idiopathic rapid-eye-movement sleep behaviour disorder. Lancet Neurol 2006, 5(7):552-553.
7. Steinfels G.F., Heym J., Strecker R.E., Jacobs B.L. Behavioral correlates of dopaminergic unit activity in freely moving cats. Brain Res 1983, 258:217-228.
8. Trulson M.E., Preussler D.W. Dopamine-containing ventral tegmental area neurons in freely moving cats: activity during the sleep-waking cycle and effects of stress. Exp Neurol 1984, 83:367-377.
9. Trulson M.E., Preussler D.W., Howell G.A. Activity of substantia nigra units across the sleep-waking cycle in freely moving cats. Neurosci Lett 1981, 26:183-188.
10. Maloney K.J., Mainville L., Jones B.E. c-Fos expression in dopaminergic and GABAergic neurons of the ventral mesencephalic tegmentum after paradoxical sleep deprivation and recovery. Eur J Neurosci 2002, 15:774-778.
11. Feenstra M.G., Botterblom M.H., Mastenbroek S. Dopamine and noradrenaline efflux in the prefrontal cortex in the light and dark period: effects of novelty and handling and comparison to the nucleus accumbens. Neuroscience 2000, 100:741-748.
12. Lena I., Parrot S., Deschaux O., Muffat-Joly S., Sauvinet V., Renaud B., et al. Variations in extracellular levels of dopamine, noradrenaline, glutamate, and aspartate across the sleep-wake cycle in the medial prefrontal cortex and nucleus accumbens of freely moving rats. JNeurosci Res 2005, 81:891-899.
13. Lees A.J., Blackburn N.A., Campbell V.L. The nighttime problems of Parkinson's disease. Clin Neuropharmacol 1988, 11:512-519.
14. Nausieda P.A., Weiner W.J., Kaplan L.R., Weber S., Klawans H.L. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 1982, 5:183-194.
15. Tandberg E., Larsen J.P., Karlsen K. Acommunity-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998, 13:895-899.
16. Oerlemans W.G., de Weerd A.W. The prevalence of sleep disorders in patients with Parkinson's disease. A self-reported, community-based survey. Sleep Med 2002, 3:147-149.
17. Dhawan V., Healy D.G., Pal S., Chaudhuri K.R. Sleep-related problems of Parkinson's disease. Age Ageing 2006, 35:220-228.
18. Factor S.A., McAlarney T., Sanchez-Ramos J.R., Weiner W.J. Sleep disorders and sleep effect in Parkinson's disease. Mov Disord 1990, 5:280-285.
19. van Hilten B., Hoff J.I., Middelkoop H.A., van der Velde E.A., Kerkhof G.A., Wauquier A., et al. Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring. Arch Neurol 1994, 51:922-928.
20. Chaudhuri K.R., Bhattacharya K., Agapito C., Porter M.C., Mills J., Clough C. The use of cabergoline in nocturnal parkinsonian disabilities causing sleep disruption: a parallel study with controlled-release levodopa. Eur J Neurol 1999, 6:S11-S15.
21. Chaudhuri K.R., Schapira A.H. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009, 8:464-474.
22. Poewe W.H., Rascol O., Quinn N., Tolosa E., Oertel W.H., Martignoni E., et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007, 6:513-520.
23. Korner Y., Meindorfner C., Moller J.C., Stiasny-Kolster K., Haja D., Cassel W., et al. Predictors of sudden onset of sleep in Parkinson's disease. Mov Disord 2004, 19:1298-1305.
24. Ohayon M.M., Priest R.G., Zulley J., Smirne S., Paiva T. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 2002, 58:1826-1833.
25. Tracik F., Ebersbach G. Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings. Mov Disord 2001, 16:500-506.
26. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev 2005, 9:185-200.
27. Schapira A.H. Restless legs syndrome: an update on treatment options. Drugs 2004, 64:149-158.
28. Ondo W.G., Vuong K.D., Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 2002, 59:421-424.
29. Comella C.L., Goetz C.G. Akathisia in Parkinson's disease. Mov Disord 1994, 9:545-549.
30. Reuter I., Ellis C.M., Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 1999, 100:163-167.
31. Hogl B., Rothdach A., Wetter T.C., Trenkwalder C. The effect of cabergoline onsleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology 2003, 28:1866-1870.
32. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4:101-119.
33. Lang A.E., Johnson K. Akathisia in idiopathic Parkinson's disease. Neurology 1987, 37:477-481.
34. Moller J.C., Unger M., Stiasny-Kolster K., Oertel W.H. Restless Legs Syndrome (RLS) and Parkinson's disease (PD)-related disorders or different entities?. JNeurol Sci 2010, 289:135-137.
35. Angelini M., Negrotti A., Marchesi E., Bonavina G., Calzetti S. Astudy of theprevalence of restless legs syndrome in previously untreated Parkinson'sdisease patients: absence of co-morbid association. JNeurol Sci 2011, 310:286-288.
36. Gjerstad M.D., Tysnes O.B., Larsen J.P. Increased risk of leg motor restlessness but not RLS in early Parkinson disease. Neurology 2011, 77:1941-1946.
37. Schenck C.H., Bundlie S.R., Ettinger M.G., Mahowald M.W. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 1986, 9:293-308.
38. Gagnon J.F., Bedard M.A., Fantini M.L., Petit D., Panisset M., Rompre S., et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002, 59:585-589.
39. Iranzo A., Molinuevo J.L., Santamaria J., Serradell M., Marti M.J., Valldeoriola F., et al. Rapid-eye-movement sleep behaviour disorder as an early marker fora neurodegenerative disorder: a descriptive study. Lancet Neurol 2006, 5:572-577.
40. Gagnon J.F., Postuma R.B., Mazza S., Doyon J., Montplaisir J. Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol 2006, 5:424-432.
41. Claassen D.O., Josephs K.A., Ahlskog J.E., Silber M.H., Tippmann-Peikert M., Boeve B.F. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010, 75:494-499.
42. Postuma R.B., Gagnon J.F., Vendette M., Fantini M.L., Massicotte-Marquez J., Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009, 72:1296-1300.
43. Iranzo A. Sleep-wake changes in the premotor stage of Parkinson disease. JNeurol Sci 2011, 310:283-285.
44. Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004, 318:121-134.
45. Braak H., Rub U., Gai W.P., Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. JNeural Transm 2003, 110:517-536.
46. Azuma T., Cruz R.F., Bayles K.A., Tomoeda C.K., Montgomery E.B. Alongitudinal study of neuropsychological change in individuals with Parkinson's disease. Int J Geriatr Psychiatry 2003, 18:1115-1120.
47. Grinberg L.T., Rueb U., Alho A.T., Heinsen H. Brainstem pathology and non-motor symptoms in PD. JNeurol Sci 2010, 289:81-88.
48. Boeve B.F., Silber M.H., Saper C.B., Ferman T.J., Dickson D.W., Parisi J.E., et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007, 130:2770-2788.
49. Przedborski S., Tieu K., Perier C., Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. JBioenerg Biomembr 2004, 36:375-379.
50. Langston J.W., Forno L.S., Rebert C.S., Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 1984, 292:390-394.
51. Verhave P.S., Jongsma M.J., Van den Berg R.M., Vis J.C., Vanwersch R.A., Smit A.B., et al. REM sleep behavior disorder in the marmoset MPTP model of early Parkinson disease. Sleep 2011, 34:1119-1125.
52. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridium by dopamine neurons explain selective toxicity. Proc Natl Acad Sci U S A 1985, 82:2173-2177.
53. Mayer R.A., Kindt M.V., Heikkila R.E. Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport. JNeurochem 1986, 47:1073-1079.
54. Burke R.E., Dauer W.T., Vonsattel J.P. Acritical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 2008, 64:485-491.
55. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
56. Albin R.L., Koeppe R.A., Chervin R.D., Consens F.B., Wernette K., Frey K.A., et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000, 55:1410-1412.
57. Gilman S., Koeppe R.A., Chervin R.D., Consens F.B., Little R., An H., et al. REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA. Neurology 2003, 61:29-34.
58. Eisensehr I., Linke R., Tatsch K., Kharraz B., Gildehaus J.F., Wetter C.T., et al. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls. Sleep 2003, 26:507-512.
59. Forno L.S., Langston J.W., DeLanney L.E., Irwin I., Ricaurte G.A. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 1986, 20449-20455.
60. Pungor K., Papp M., Kekesi K., Juhasz G. Anovel effect of MPTP: the selective suppression of paradoxical sleep in cats. Brain Res 1990, 525:310-314.
61. Almirall H., Bautista V., Sanchez-Bahillo A., Trinidad-Herrero M. Ultradian and circadian body temperature and activity rhythms in chronic MPTP treated monkeys. Neurophysiol Clin 2001, 31:161-170.
62. Monaca C., Laloux C., Jacquesson J.M., Gele P., Marechal X., Bordet R., et al. Vigilance states in a parkinsonian model, the MPTP mouse. Eur J Neurosci 2004, 20:2474-2478.
63. Dzirasa K., Ribeiro S., Costa R., Santos L.M., Lin S.C., Grosmark A., et al. Dopaminergic control of sleep-wake states. JNeurosci 2006, 26:10577-10589.
64. Dahan L., Astier B., Vautrelle N., Urbain N., Kocsis B., Chouvet G. Prominent burst firing of dopaminergic neurons in the ventral tegmental area during paradoxical sleep. Neuropsychopharmacology 2007, 32:1232-1241.
65. Laloux C., Derambure P., Jacquesson J.M., Bordet R., Destee A., Monaca C. The effects of serotoninergic, noradrenergic, cholinergic and dopaminergic drugs on vigilance states in MPTP-treated mice. Brain Res 2007, 1161:79-87.
66. De Cock V.C., Vidailhet M., Leu S., Texeira A., Apartis E., Elbaz A., et al. Restoration of normal motor control in Parkinson's disease during REM sleep. Brain 2007, 130:450-456.
67. Lima M.M.S., Andersen M.L., Reksidler A.B., Silva A., Zager A., Zanata S.M., et al. Blockage of dopaminergic D(2) receptors produces decrease of REM but not of slow wave sleep in rats after REM sleep deprivation. Behav Brain Res 2008, 188:406-411.
68. Garcia-Garcia F., Ponce S., Brown R., Cussen V., Krueger J.M. Sleep disturbances in the rotenone animal model of Parkinson disease. Brain Res 2005, 1042:160-168.
69. Lima M.M.S., Andersen M.L., Reksidler A.B. Vital MABF, Tufik S. The role of the substantia nigra pars compacta in regulating sleep patterns in rats. PLoS ONE 2007, 2:e513.
70. Barraud Q., Lambrecq V., Forni C., McGuire S., Hill M., Bioulac B., et al. Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp Neurol 2009, 219:574-582.
71. Laloux C., Derambure P., Kreisler A., Houdayer E., Bruezière S., Bordet R., et al. MPTP-treated mice: long-lasting loss of nigral TH-ir neurons but not paradoxical sleep alterations. Exp Brain Res 2008, 186:635-642.
72. Marin O., Smeets W.J., Gonzalez A. Evolution of the basal ganglia in tetrapods: a new perspective based on recent studies in amphibians. Trends Neurosci 1998, 21:487-494.
73. Winn P. Frontal syndrome as a consequence of lesions in the pedunculopontine tegmental nucleus: a short theoretical review. Brain Res Bull 1998, 47:551-563.
74. Forster G.L., Blaha C.D. Pedunculopontine tegmental stimulation evokes striatal dopamine efflux by activation of acetylcholine and glutamate receptors in the midbrain and pons of the rat. Eur J Neurosci 2003, 17:751-762.
75. Lima M.M.S., Reksidler A.B., Vital M.A. The neurobiology of the substantia nigra pars compacta: from motor to sleep regulation. JNeural Transm Suppl 2009, 73:135-145.
76. Lima M.M.S., Reksidler A.B., Vital M.A.B.F. The dopaminergic dilema: sleep or wake? implications in Parkinson's disease. Biosci Hypothesis 2008, 1:9-13.
77. Carlson J.D., Pearlstein R.D., Buchholz J., Iacono R.P., Maeda G. Regional metabolic changes in the pedunculopontine nucleus of unilateral 6-hydroxydopamine Parkinson's model rats. Brain Res 1999, 828:12-19.
78. Orieux G., Francois C., Feger J., Yelnik J., Vila M., Ruberg M., et al. Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease. Neuroscience 2000, 97:79-88.
79. Gomez-Gallego M., Fernandez-Villalba E., Fernandez-Barreiro A., Herrero M.T. Changes in the neuronal activity in the pedunculopontine nucleus in chronic MPTP-treated primates: an in situ hybridization study of cytochrome oxidase subunit I, choline acetyl transferase and substance P mRNA expression. JNeural Transm 2007, 114:319-326.
80. Zhang Q.J., Liu J., Wang Y., Wang S., Wu Z.H., Yan W., et al. The firing activity of presumed cholinergic and non-cholinergic neurons of the pedunculopontine nucleus in 6-hydroxydopamine-lesioned rats: an invivo electrophysiological study. Brain Res 2008, 1243:152-160.
81. Blaha C.D., Winn P. Modulation of dopamine efflux in the striatum following cholinergic stimulation of the substantia nigra in intact and pedunculopontine tegmental nucleus-lesioned rats. JNeurosci 1993, 13:1035-1044.
82. Oades R.D., Halliday G.M. Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity. Brain Res 1987, 434:117-165.
83. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J., et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990, 250:1429-1432.
84. Bonuccelli U., Del Dotto P. New pharmacologic horizons in the treatment of Parkinson disease. Neurology 2006, 67:S30-S38.
85. Hirsch E.C., Graybiel A.M., Duyckaerts C., Javoy-Agid F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci U S A 1987, 84:5976-5980.
86. Mena-Segovia J., Bolam J.P., Magill P.J. Pedunculopontine nucleus and basal ganglia: distant relatives or part of the same family?. Trends Neurosci 2004, 27:585-588.